Rebecca Ivy Hartman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 40 | 2023 | 5662 | 6.050 |
Why?
|
Melanoma | 23 | 2023 | 5462 | 3.680 |
Why?
|
Sunscreening Agents | 6 | 2023 | 132 | 2.160 |
Why?
|
Sunburn | 3 | 2023 | 155 | 1.780 |
Why?
|
Veterans | 4 | 2023 | 2513 | 1.280 |
Why?
|
Sunbathing | 2 | 2023 | 60 | 1.030 |
Why?
|
Protective Clothing | 3 | 2023 | 102 | 1.020 |
Why?
|
Lymphangitis | 1 | 2023 | 12 | 0.920 |
Why?
|
Dermatology | 5 | 2021 | 870 | 0.910 |
Why?
|
Mycobacterium marinum | 1 | 2023 | 26 | 0.910 |
Why?
|
Niacinamide | 2 | 2023 | 416 | 0.860 |
Why?
|
Chemoprevention | 2 | 2023 | 319 | 0.850 |
Why?
|
Prurigo | 1 | 2022 | 21 | 0.840 |
Why?
|
Mohs Surgery | 2 | 2021 | 197 | 0.830 |
Why?
|
Self-Examination | 1 | 2022 | 70 | 0.820 |
Why?
|
Benzene | 1 | 2021 | 100 | 0.780 |
Why?
|
Dermatofibrosarcoma | 1 | 2021 | 62 | 0.780 |
Why?
|
Hair Color | 1 | 2020 | 136 | 0.720 |
Why?
|
Skin Diseases | 6 | 2021 | 1065 | 0.670 |
Why?
|
Directive Counseling | 1 | 2020 | 166 | 0.670 |
Why?
|
Carcinoma, Basal Cell | 1 | 2023 | 545 | 0.610 |
Why?
|
Keratinocytes | 1 | 2021 | 797 | 0.580 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 687 | 0.560 |
Why?
|
Disabled Persons | 2 | 2023 | 1209 | 0.490 |
Why?
|
Lip Diseases | 1 | 2013 | 18 | 0.460 |
Why?
|
Stenotrophomonas maltophilia | 1 | 2013 | 16 | 0.450 |
Why?
|
Secondary Prevention | 1 | 2020 | 1520 | 0.450 |
Why?
|
Dyskeratosis Congenita | 1 | 2014 | 72 | 0.450 |
Why?
|
Granuloma Annulare | 1 | 2013 | 28 | 0.450 |
Why?
|
Early Detection of Cancer | 4 | 2021 | 3070 | 0.440 |
Why?
|
United States | 21 | 2023 | 69693 | 0.440 |
Why?
|
Primary Prevention | 1 | 2020 | 1166 | 0.420 |
Why?
|
Parotid Neoplasms | 1 | 2013 | 155 | 0.410 |
Why?
|
Lip | 1 | 2013 | 195 | 0.400 |
Why?
|
Dermatitis | 1 | 2013 | 197 | 0.390 |
Why?
|
Humans | 64 | 2023 | 742088 | 0.390 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2013 | 232 | 0.390 |
Why?
|
Forecasting | 2 | 2017 | 2948 | 0.390 |
Why?
|
Biomedical Research | 2 | 2016 | 3306 | 0.360 |
Why?
|
Skin | 5 | 2023 | 4353 | 0.360 |
Why?
|
Career Choice | 1 | 2016 | 743 | 0.350 |
Why?
|
Ultraviolet Rays | 3 | 2023 | 1059 | 0.350 |
Why?
|
Psoriasis | 1 | 2017 | 898 | 0.340 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3766 | 0.330 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2014 | 475 | 0.320 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 24913 | 0.310 |
Why?
|
Immunocompromised Host | 1 | 2013 | 847 | 0.310 |
Why?
|
Mental Health | 1 | 2020 | 2997 | 0.280 |
Why?
|
Biopsy | 7 | 2021 | 6756 | 0.270 |
Why?
|
Physical Examination | 2 | 2022 | 1239 | 0.260 |
Why?
|
Radiation Dosage | 1 | 2014 | 1927 | 0.260 |
Why?
|
Dermoscopy | 2 | 2023 | 56 | 0.240 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3915 | 0.230 |
Why?
|
Rectal Neoplasms | 1 | 2012 | 1195 | 0.220 |
Why?
|
Adhesives | 1 | 2023 | 61 | 0.220 |
Why?
|
Private Practice | 1 | 2023 | 154 | 0.220 |
Why?
|
Habits | 1 | 2023 | 137 | 0.210 |
Why?
|
Decision Support Techniques | 1 | 2012 | 1952 | 0.210 |
Why?
|
Pregnancy Complications | 1 | 2016 | 2861 | 0.200 |
Why?
|
Health Surveys | 2 | 2023 | 4030 | 0.200 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2023 | 701 | 0.190 |
Why?
|
Nevus, Halo | 1 | 2020 | 6 | 0.190 |
Why?
|
Lymph Nodes | 1 | 2012 | 3465 | 0.190 |
Why?
|
Mental Disorders | 1 | 2020 | 6587 | 0.190 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 647 | 0.190 |
Why?
|
Sunlight | 1 | 2022 | 325 | 0.190 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2020 | 76 | 0.190 |
Why?
|
Current Procedural Terminology | 1 | 2021 | 92 | 0.180 |
Why?
|
Gender Identity | 3 | 2020 | 681 | 0.180 |
Why?
|
Registries | 3 | 2022 | 8077 | 0.180 |
Why?
|
Research Design | 1 | 2016 | 5979 | 0.180 |
Why?
|
Honey | 1 | 2019 | 11 | 0.180 |
Why?
|
Folliculitis | 1 | 2019 | 28 | 0.170 |
Why?
|
Scalp Dermatoses | 1 | 2019 | 40 | 0.170 |
Why?
|
Health Behavior | 2 | 2023 | 2630 | 0.170 |
Why?
|
Staphylococcal Skin Infections | 1 | 2019 | 75 | 0.170 |
Why?
|
Mycosis Fungoides | 1 | 2020 | 163 | 0.160 |
Why?
|
Vitamin B Complex | 1 | 2021 | 288 | 0.160 |
Why?
|
Pandemics | 3 | 2023 | 8328 | 0.160 |
Why?
|
Adult | 16 | 2022 | 213712 | 0.160 |
Why?
|
Skin Pigmentation | 1 | 2020 | 281 | 0.160 |
Why?
|
Heterosexuality | 1 | 2020 | 271 | 0.160 |
Why?
|
Exanthema | 1 | 2022 | 488 | 0.150 |
Why?
|
SEER Program | 1 | 2022 | 1507 | 0.150 |
Why?
|
Risk Factors | 8 | 2022 | 72145 | 0.140 |
Why?
|
Demography | 1 | 2022 | 1650 | 0.140 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 874 | 0.140 |
Why?
|
Incidence | 3 | 2023 | 20928 | 0.140 |
Why?
|
Matrix Metalloproteinase 14 | 2 | 2006 | 61 | 0.140 |
Why?
|
Research Subjects | 1 | 2018 | 238 | 0.140 |
Why?
|
Neoplasm Staging | 4 | 2023 | 11001 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 802 | 0.140 |
Why?
|
Prognosis | 5 | 2023 | 29010 | 0.140 |
Why?
|
Alopecia | 1 | 2019 | 381 | 0.130 |
Why?
|
Prediabetic State | 1 | 2020 | 493 | 0.130 |
Why?
|
Hemangioma | 1 | 2020 | 737 | 0.130 |
Why?
|
Lower Extremity | 1 | 2023 | 1151 | 0.130 |
Why?
|
Tumor Burden | 1 | 2021 | 1905 | 0.130 |
Why?
|
Female | 20 | 2022 | 379592 | 0.130 |
Why?
|
Middle Aged | 13 | 2022 | 213127 | 0.120 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1656 | 0.120 |
Why?
|
Mass Screening | 2 | 2020 | 5238 | 0.120 |
Why?
|
Retrospective Studies | 7 | 2023 | 77098 | 0.120 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2006 | 472 | 0.120 |
Why?
|
Physician Assistants | 1 | 2016 | 193 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9185 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2028 | 0.120 |
Why?
|
Health Care Surveys | 1 | 2021 | 2451 | 0.110 |
Why?
|
Male | 21 | 2022 | 349538 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2020 | 2050 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 829 | 0.110 |
Why?
|
Electronic Mail | 1 | 2015 | 213 | 0.110 |
Why?
|
Referral and Consultation | 2 | 2016 | 3527 | 0.110 |
Why?
|
Nurse Practitioners | 1 | 2016 | 270 | 0.110 |
Why?
|
Prevalence | 5 | 2020 | 15194 | 0.110 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3612 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1052 | 0.110 |
Why?
|
Interviews as Topic | 2 | 2020 | 2536 | 0.110 |
Why?
|
Xenopus laevis | 2 | 2006 | 956 | 0.100 |
Why?
|
Medical Staff, Hospital | 1 | 2016 | 603 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1780 | 0.100 |
Why?
|
Acne Vulgaris | 1 | 2016 | 297 | 0.100 |
Why?
|
Research Personnel | 1 | 2016 | 573 | 0.100 |
Why?
|
Mentors | 1 | 2016 | 630 | 0.090 |
Why?
|
Survival Analysis | 1 | 2023 | 10248 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12958 | 0.090 |
Why?
|
Cohort Studies | 3 | 2022 | 40450 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2022 | 1794 | 0.090 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5133 | 0.090 |
Why?
|
Aged | 8 | 2021 | 162944 | 0.090 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2020 | 199 | 0.090 |
Why?
|
Disclosure | 1 | 2015 | 736 | 0.080 |
Why?
|
Clinical Competence | 3 | 2021 | 4681 | 0.080 |
Why?
|
Internship and Residency | 2 | 2021 | 5774 | 0.080 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4839 | 0.080 |
Why?
|
Gene Expression Profiling | 2 | 2023 | 9410 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2450 | 0.080 |
Why?
|
Patient Preference | 1 | 2015 | 886 | 0.080 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7153 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5522 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2020 | 2187 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3151 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8621 | 0.070 |
Why?
|
Prospective Studies | 4 | 2022 | 53187 | 0.070 |
Why?
|
Metamorphosis, Biological | 1 | 2006 | 37 | 0.070 |
Why?
|
Age Factors | 1 | 2023 | 18355 | 0.070 |
Why?
|
Curriculum | 1 | 2019 | 3589 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20774 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2714 | 0.070 |
Why?
|
Prostatic Neoplasms | 2 | 2022 | 11039 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 35342 | 0.060 |
Why?
|
Risk Assessment | 3 | 2023 | 23320 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1679 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2906 | 0.060 |
Why?
|
Primary Health Care | 2 | 2023 | 4551 | 0.060 |
Why?
|
Prostatectomy | 1 | 2013 | 1871 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3584 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 2853 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7276 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5304 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11472 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2022 | 39004 | 0.050 |
Why?
|
Acantholysis | 1 | 2022 | 11 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2022 | 57683 | 0.050 |
Why?
|
Ichthyosis | 1 | 2022 | 60 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40054 | 0.050 |
Why?
|
Elastic Tissue | 1 | 2020 | 65 | 0.050 |
Why?
|
Hypopigmentation | 1 | 2020 | 41 | 0.050 |
Why?
|
Telangiectasis | 1 | 2020 | 75 | 0.050 |
Why?
|
Skin Abnormalities | 1 | 2020 | 60 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14720 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2019 | 62966 | 0.040 |
Why?
|
Cephalexin | 1 | 2019 | 37 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 170 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11363 | 0.040 |
Why?
|
Hyperpigmentation | 1 | 2020 | 112 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2022 | 617 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2019 | 276 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4440 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 628 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3239 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 778 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15056 | 0.040 |
Why?
|
Physicians | 1 | 2015 | 4554 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 11695 | 0.040 |
Why?
|
Atrophy | 1 | 2020 | 1576 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2010 | 3123 | 0.030 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 3215 | 0.030 |
Why?
|
Attitude to Computers | 1 | 2015 | 202 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29087 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2593 | 0.030 |
Why?
|
Video Recording | 1 | 2019 | 944 | 0.030 |
Why?
|
Health Records, Personal | 1 | 2015 | 124 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2010 | 4229 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3266 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2615 | 0.030 |
Why?
|
Adolescent | 3 | 2020 | 85649 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2885 | 0.030 |
Why?
|
Dermatologic Agents | 1 | 2016 | 274 | 0.030 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 431 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2016 | 414 | 0.030 |
Why?
|
Plant Proteins | 1 | 1994 | 364 | 0.030 |
Why?
|
Qualitative Research | 1 | 2020 | 2680 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2935 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 925 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2594 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2107 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2295 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3256 | 0.020 |
Why?
|
Genetic Testing | 1 | 2022 | 3439 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2900 | 0.020 |
Why?
|
Self Report | 1 | 2020 | 3548 | 0.020 |
Why?
|
Oligopeptides | 1 | 1994 | 1176 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3211 | 0.020 |
Why?
|
Young Adult | 3 | 2020 | 56350 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2533 | 0.020 |
Why?
|
Markov Chains | 1 | 2010 | 969 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2283 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3014 | 0.020 |
Why?
|
Incidental Findings | 1 | 2010 | 688 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2006 | 3617 | 0.020 |
Why?
|
Base Sequence | 2 | 2006 | 12797 | 0.020 |
Why?
|
Population Surveillance | 1 | 2015 | 2616 | 0.020 |
Why?
|
Triiodothyronine | 1 | 2006 | 494 | 0.010 |
Why?
|
Catalytic Domain | 1 | 2006 | 699 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1679 | 0.010 |
Why?
|
Life Expectancy | 1 | 2010 | 1183 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9941 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1723 | 0.010 |
Why?
|
Internet | 1 | 2015 | 3062 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3203 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3391 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 19862 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2006 | 1213 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2006 | 2335 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6365 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 2006 | 1546 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3839 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1624 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2006 | 3701 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13403 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2006 | 4322 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3847 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2006 | 13814 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2006 | 1740 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 18112 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5385 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6608 | 0.010 |
Why?
|
Decision Making | 1 | 2010 | 3869 | 0.010 |
Why?
|
Algorithms | 1 | 2016 | 13853 | 0.010 |
Why?
|
DNA | 1 | 2006 | 7289 | 0.010 |
Why?
|
Animals | 2 | 2006 | 168561 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1994 | 3760 | 0.000 |
Why?
|